Press release
Alzheimer's Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc.
Alzheimer's Disease Pipeline Insights
Alzheimer's Disease Overview:
Alzheimer's disease (AD) is a neurodegenerative disorder and the leading cause of dementia, characterized by a decline in cognitive function and the ability to perform daily activities. AD is considered multifactorial, with two main theories proposed: the cholinergic and amyloid hypotheses. Several risk factors, including aging, genetics, head injuries, vascular diseases, infections, and environmental influences, contribute to the disease.
Neuropathologically, AD is marked by two types of lesions: (1) positive lesions, which include neurofibrillary tangles, amyloid plaques, and other deposits, and (2) negative lesions, which involve brain atrophy due to neural, neuropil, and synaptic loss. Other factors such as neuroinflammation, oxidative stress, and cholinergic neuron damage also contribute to neurodegeneration.
AD is categorized into three stages based on cognitive impairment: preclinical, mild, and dementia. The disease typically starts with short-term memory loss, followed by difficulty in problem-solving, judgment, and executive functioning. As the disease progresses, language and visuospatial skills decline, and neuropsychiatric symptoms like apathy, agitation, and psychosis emerge. In advanced stages, patients experience motor difficulties, sleep disturbances, and physical dependence, eventually requiring full caregiver assistance.
Request for a detailed insights report on Alzheimer's Disease pipeline insights @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Alzheimer's Disease Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Alzheimer's Disease Therapeutics Market.
Key Takeaways from the Alzheimer's Disease Pipeline Report
DelveInsight's Alzheimer's Disease pipeline report depicts a robust space with 110+ active players working to develop 120+ pipeline therapies for Alzheimer's Disease treatment.
In September 2024, Japan's Ministry of Health, Labour, and Welfare approved KISUNLA (donanemab-azbt, 350 mg/20 mL) for intravenous infusion every four weeks. Developed by Eli Lilly, this drug is aimed at treating adults with early symptomatic Alzheimer's disease, including mild dementia, who have confirmed amyloid pathology.
In July 2024, the FDA granted approval to Eli Lilly's donanemab, an anti-amyloid antibody, making it the third drug aimed at modifying the progression of Alzheimer's disease. This approval is set to increase competition between Eli Lilly's donanemab and Biogen and Eisai's ADUHELM (aducanumab) and LEQEMBI (lecanemab).
Key Alzheimer's Disease companies such as AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc., Cassava Sciences, BioVie Inc., Novo Nordisk, Alector Inc., Longeveron Inc., Cognition Therapeutics, TrueBinding, Inc., VT BIO, Luye Pharma Group Ltd., Lexeo Therapeutics, Merck Sharp & Dohme LLC, Regeneration Biomedical, Alnylam Pharmaceuticals, Sinotau Pharmaceutical Group, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., and others are evaluating new drugs for Alzheimer's Disease to improve the treatment landscape.
Promising Alzheimer's Disease pipeline therapies in various stages of development include AR1001, NE3107, LY3372689, CT1812, ABBV-916, ALX-001, and others.
Alzheimer's Disease Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Alzheimer's Disease Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's Disease treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Alzheimer's Disease market.
Download our free sample page report on Alzheimer's Disease pipeline insights @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Alzheimer's Disease Emerging Drugs
AR1001: AriBio Co., Ltd.
NE3107: BioVie
LY3372689: Eli Lilly & Co.
CT1812: Cognition Therapeutics
ABBV-916: AbbVie Inc.
ALX-001: Allyx Therapeutics, Inc.
Alzheimer's Disease Companies
There are over 110 key companies working on developing therapies for Alzheimer's disease. Among them, AriBio Co., Ltd. and BioVie have Alzheimer's disease drug candidates in the most advanced stage, Phase III.
DelveInsight's report covers around 120+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Alzheimer's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Alzheimer's Disease Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Alzheimer's Disease Therapies and Key Companies: Alzheimer's Disease Clinical Trials and advancements @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Alzheimer's Disease Pipeline Therapeutic Assessment
• Alzheimer's Disease Assessment by Product Type
• Alzheimer's Disease By Stage
• Alzheimer's Disease Assessment by Route of Administration
• Alzheimer's Disease Assessment by Molecule Type
Download Alzheimer's Disease Sample report to know in detail about the Alzheimer's Disease treatment market @ Alzheimer's Disease Therapeutic Assessment @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Alzheimer's Disease Current Treatment Patterns
4. Alzheimer's Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Alzheimer's Disease Late-Stage Products (Phase-III)
7. Alzheimer's Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Alzheimer's Disease Discontinued Products
13. Alzheimer's Disease Product Profiles
14. Alzheimer's Disease Key Companies
15. Alzheimer's Disease Key Products
16. Dormant and Discontinued Products
17. Alzheimer's Disease Unmet Needs
18. Alzheimer's Disease Future Perspectives
19. Alzheimer's Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Alzheimer's Disease Pipeline Reports Offerings: https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therapeutics, Inc. here
News-ID: 3816573 • Views: …
More Releases from DelveInsight Business Research LLP
Gonorrhoea Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Tri …
DelveInsight's "Gonorrhoea Pipeline Insight 2025" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Gonorrhoea pipeline landscape. It covers the Gonorrhoea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gonorrhoea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Gonorrhoea pipeline products in this space.
Explore our latest breakthroughs in Gonorrhoea Research. Learn…
Glioblastoma Multiforme Market Size (7MM) was ~USD 835 million in 2023 and is ex …
DelveInsight's "Glioblastoma Multiforme Market Insight, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of GBM, historical and forecasted epidemiology as well as the GBM market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Glioblastoma Multiforme Market with DelveInsight's In-Depth Report @ Glioblastoma Multiforme Market Size- https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Glioblastoma Multiforme Market Report
• In…
Blepharitis Treatment Market Size in the 7MM is expected to grow by 2034, estima …
DelveInsight's "Blepharitis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Blepharitis, historical and forecasted epidemiology, as well as the Blepharitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Blepharitis Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Blepharitis Market Forecast @ https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
CAR-T in NHL Treatment Market Size is estimated to grow by 2034, estimates Delve …
DelveInsight's "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma, historical and forecasted epidemiology, as well as the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
